Flibanserin (code name BIMT-17), proposed trade name Girosa and Addyi, is a drug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD). Development by Boehringer Ingelheim was halted in October 2010 following a negative report by the U.S. Food and Drug Administration. The rights to the drug were then transferred to Sprout Pharmaceuticals which is continuing the drug development process.
Leave a Reply